According to Zen Score, the 3 best pharma stocks to buy right now are:
1. Neurocrine Biosciences (NASDAQ:NBIX)
Neurocrine Biosciences (NASDAQ:NBIX) is the top pharmaceutical stock with a Zen Score of 64, which is 39 points higher than the pharmaceutical industry average of 25. It passed 21 out of 33 due diligence checks and has strong fundamentals. Neurocrine Biosciences has seen its stock return 27.79% over the past year, overperforming other pharmaceutical stocks by 40 percentage points.
Neurocrine Biosciences has an average 1 year
price target of $142.44, an upside of 7.47% from Neurocrine Biosciences's current stock price of $132.54.
Neurocrine Biosciences stock has a consensus Buy recommendation according to Wall Street analysts. Of the 16 analysts covering Neurocrine Biosciences, 43.75% have issued a Strong Buy rating, 18.75% have issued a Buy, 37.5% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.
2. Kamada (NASDAQ:KMDA)
Kamada (NASDAQ:KMDA) is the second best pharmaceutical stock with a Zen Score of 61, which is 36 points higher than the pharmaceutical industry average of 25. It passed 19 out of 33 due diligence checks and has strong fundamentals. Kamada has seen its stock return 8.74% over the past year, overperforming other pharmaceutical stocks by 21 percentage points.
Kamada has an average 1 year
price target of $11.00, an upside of 115.69% from Kamada's current stock price of $5.10.
Kamada stock has a consensus Buy recommendation according to Wall Street analysts. Of the 1 analyst covering Kamada, 0% have issued a Strong Buy rating, 100% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.
3. Siga Technologies (NASDAQ:SIGA)
Siga Technologies (NASDAQ:SIGA) is the third best pharmaceutical stock with a Zen Score of 58, which is 33 points higher than the pharmaceutical industry average of 25. It passed 21 out of 38 due diligence checks and has strong fundamentals. Siga Technologies has seen its stock return 42.14% over the past year, overperforming other pharmaceutical stocks by 54 percentage points.